Goal for Alzheimer's drug by 2025 too ambitious?

SUMMARY: The National Alzheimer's Project Act requires a blueprint for curing Alzheimer's, a brain disease that causes dementia, by 2025.
How do you feel about this topic?
  • Happy
  • Inspired
  • Reassured
  • Confused
  • Angry
  • Sad
  • Frustrated
  • Informed
sponsored by:

CHICAGO (Reuters) - The U.S. government has set a deadline of 2025 for finding an effective way to treat or prevent Alzheimer's disease, an ambitious target considering there is no cure on the horizon and one that sets a firm deadline unlike previous campaigns against cancer or AIDS.

A panel of Alzheimer's experts this week has been fleshing out the first comprehensive plan by the U.S. Department of Health and Human Services (HHS) to fight Alzheimer's disease, an effort mandated by the National Alzheimer's Project Act signed into law by President Barack Obama last year.

The law called for the government to create a blueprint to beat Alzheimer's but provided no new money for the effort.

More than 5 million Americans suffer from Alzheimer's, a brain disease that causes dementia and affects primarily elderly people. Some experts estimate the disease costs the United States more than $170 billion annually to treat.

Australia, France and South Korea already have comprehensive Alzheimer's plans, and global experts have been urging the United States to take a leadership role.

"We want to demonstrate that as a country we are committed to addressing this issue," Dr. Howard Koh, assistant secretary for health at HHS, told Reuters in a telephone interview.

"We know the projected number of patients is expected to rise in the future. We know there are far too many patients who are suffering from this devastating condition and it is affecting them and their caregivers," Koh said.

The U.S. plan is meant to galvanize efforts to fight the fatal disease that robs victims of their ability to think and drains the resources of family caregivers.

But some experts say the 2025 deadline is unrealistic.

"No one set a deadline for the 'War on cancer' or in the fight against HIV/AIDS. We make progress and we keep fighting. The same should be true for Alzheimer's," said Dr. Sam Gandy, an Alzheimer's researcher at Mount Sinai School of Medicine.

"In my mind, that provides the unfortunate sense that we will have 'failed' if we don't have a cure by 2025."

When U.S. President Richard Nixon declared war on cancer in 1971 and signed the National Cancer Act, the idea was to dedicate the same kinds of funds and resources to cancer as had been spent on splitting the atom.

In the 30-year fight against AIDS, it was only last November, with many effective treatments already in hand, that U.S. Secretary of State Hillary Clinton set a goal for an AIDS-free generation, something she said "would have been unimaginable just a few years ago."

By contrast, the National Alzheimer's Project Act provides no new money. And while a few drug companies have compounds in clinical trials, researchers say they are just starting to understand the disease, which develops silently for 15 to 20 years before any memory problems begin to show.

"This means that if we had, today, already in hand, the funding, recruitment and the perfect drug, the trial would still take 15 to 20 years," Gandy said.

Despite costly efforts, no drug has been found that can keep the disease from progressing. Some researchers fear drug companies will give up entirely.

The latest blow came on Tuesday, when Pfizer Inc said it would end its collaboration with Medivation Inc after the drug Dimebon failed to improve thinking ability in a late-stage trial.

"Our best shot is not at a cure but at prevention, and prevention trials for Alzheimer's will be larger, more time-consuming and more expensive than any prevention trials ever undertaken," Gandy said in an email.

Alzheimer's Research and Funding

Related Articles


Latest News in Health